Navigation Links
U of T-led study cracks universal RNA code, suggests a new cause for autism
Date:7/12/2013

The discovery cracks the "RNA control code," which dictates how RNA a family of molecules that mediates DNA expression moves genetic information from DNA to create proteins.

"For the first time, we understand the language of a code that is essential to gene processing," said Quaid Morris, a Professor in U of T's Donnelly Centre for Cellular and Biomolecular Research and the Banting and Best Department of Medical Research. "Many human diseases are due to defects in this code, so figuring out what it means is crucial to creating new treatments for many conditions."

The scientific journal Nature published the study results in its July 11, 2013 issue.

The researchers translated the code with a biochemical technique developed by a research scientist in Hughes' lab, Debashish Ray, and a student in Morris's lab, Hilal Kazan. The team defined the meaning of "words" in RNA, allowing identification of patterns in RNA molecules that proteins use to control RNA processing and movement, which are often altered in disease.

One protein they looked at may explain some of the symptoms in children with autism. The researchers found that RBFOX1, a protein often turned off in the brains of patients, ensures the activity of genes important for the function of nerve cells in the brain.

"This was a surprising finding, because we knew RBFOX1 controls gene expression, but had no idea it also stabilizes RNA," said Tim Hughes, a Professor in the Department of Molecular Genetics and the Donnelly Centre. "It's a good example of the predictive power of the RNA control code, which we think will really open up the field of gene regulation."

Hughes said the work also shows that the RNA control code may be easier to interpret than a similar control code in DNA. Researchers have been struggling for years to understand this DNA control code, but the new results suggest RNA control could offer a more fruitful area of inquiry, with autism as just one example.

The team is now working with autism experts to assess the potential of RBFOX1 in autism therapies, and exploring promising leads on the roles of unstudied proteins in many other diseases.


'/>"/>

Contact: Jim Oldfield
jim.oldfield@utoronto.ca
416-946-8423
University of Toronto
Source:Eurekalert

Related biology news :

1. Vanderbilt-led team to develop microbrain to improve drug testing
2. Study finds surprising benefits about diary cow inflammation
3. Metastatic pancreatic, primary breast cancer have common growth mechanisms, study suggests
4. Journal highlights Arctic sea ice study by UM professor
5. Innovative MIT study estimates extent to which air pollution in China shortens human lives
6. Temperature increases causing tropical forests to blossom, according to study
7. New study reveals important role of insulin in making breast milk
8. Study reveals ancient jigsaw puzzle of past supercontinent
9. Reproductive BioMedicine Online publishes study on assisted reproduction
10. Lifesaving HIV treatment could reach millions more people following landmark study
11. Low levels of toxic proteins linked to brain diseases, study suggests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2019)... ... January 03, 2019 , ... Over the last ... their drug discovery research workflows with biology ranging from single cell-type spheroids to ... in vitro studies, they create several challenges that need to be overcome in ...
(Date:12/25/2018)... , ... December 24, 2018 , ... ... The Rockefeller University have discovered a new use for a long-standing computational concept ... spam control, blocking unwanted files and messages. Using blacklisting as a filter to ...
(Date:12/19/2018)... ... , ... InTouchMD’s flagship product, Pulse , has been honored by PM360 ... is featuring the recognition in its 7th annual Innovations issue, created for purpose of ... medical device industries. , “This recognition comes at an exciting time for Pulse as ...
Breaking Biology News(10 mins):
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos Medicine Inc. ... Disease drug candidate, code-named "KM-819." KM-819 is an orally active small molecule ... in South Korea. , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study ...
(Date:12/20/2018)... ... , ... New Year’s brings reflection and desire to improve for individuals and ... (EU) on the horizon, Jim Kasic, president and CEO of Boulder iQ, suggests five ... Device Regulation (MDR), digital health, and big data are just a few of the ...
(Date:12/18/2018)... ... ... Patients with early stages of breast cancer who undergo partial breast proton ... irradiation, a new study suggests. , Patients with early stage breast cancer — stage ... the cancerous tumor because there is a 30 to 40 percent change the disease ...
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial ... (human) ingredient. This has been part of their strategic plan and an important ... certification creates custom fermentation opportunities for MDG within the $44 Billion human probiotic ...
Breaking Biology Technology: